Temasek

Investment focus

Temasek's portfolio on More Capital spans food & agriculture, fintech, blockchain & web3, clean energy & climate. Of the 15 portfolio companies tracked here, 13 have publicly reported valuations totaling approximately $84B.

If your company is backed by Temasek

Employees at companies backed by Temasek may encounter this fund's name on their cap table, in board communications, or in funding announcements. Understanding who invests in your employer can provide useful context when evaluating your equity.

What this means for your stock

Institutional investors like Temasek typically hold preferred shares with rights that differ from the common stock or options held by employees. In a liquidity event, preferred shareholders may have liquidation preferences, anti-dilution protections, or board-level governance rights that affect the value of common equity. The specific terms depend on each company's funding agreements.

Secondary market considerations

Some venture-backed companies allow employees to sell shares on secondary markets, while others restrict transfers. Whether your company permits secondary sales, and under what conditions, is typically governed by the company's equity plan and any applicable right-of-first-refusal provisions — not by the fund itself. However, the presence of institutional investors can sometimes signal the maturity and governance structure of the company.

Temasek portfolio companies

15 companies tracked on More Capital, sorted by reported valuation. 2 companies do not have a publicly reported valuation.

Top holdings by valuation

By sector

Latest Temasek news

Syneron Bio Announces Completion of $150 Million Series B Financing

BEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Decheng Capital, and CDH VGC. Additional investors included a wholly owned subsidiary of the Abu Dhabi Investment Authority ('ADIA'), True Light Capital, - an independent, wholly-owned subsidiary of Temasek, Qiming Venture Partners, BioTrack Capital and well known industrial investors. Existing shareholders, including AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund and Lenovo Capital,  among others, also continued their support.

The Manila TimesApr 3, 2026

D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs

**media[861336]**SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors - WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi - also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio's innovative pipeline and its global development strategy.

The Manila TimesDec 10, 2025

Industries invested in

• Fintech
• Cybersecurity
• Food & Agriculture
• Insurance & Insurtech
• Blockchain & Web3
• Clean Energy & Climate
• Consumer & Social
• Transportation & Logistics

Frequent co-investors

Funds that most frequently co-invest alongside Temasek in the same companies.